Antitumour metal compounds: more than theme and variations
Citations Over TimeTop 1% of 2007 papers
Abstract
Triggered by the resounding success of cisplatin, the past decades have seen tremendous efforts to produce clinically beneficial analogues. The recent achievement of oxaliplatin for the treatment of colon cancer should, however, not belie the imbalance between a plethora of investigated complexes and a very small number of clinically approved platinum drugs. Strategies opening up new avenues are increasingly being sought using complexes of metals other than platinum such as ruthenium or gallium. Based on the chemical differences between these metals, the spectrum of molecular mechanisms of action and potential indications can be broadened substantially. Other approaches focus on complexes with tumour-targeting properties, thereby maximizing the impact on cancer cells and minimizing the problem of adverse side effects, and complexes with biologically active ligands.
Related Papers
- → Fresh Platinum Complexes with Promising Antitumor Activity(2010)74 cited
- → Naphthalimide Platinum(IV) Compounds as Antitumor Agents with Dual DNA Damage Mechanism to Overcome Cisplatin Resistance(2018)16 cited
- Accumulation of novel transplatinum complexes in cisplatin and oxaliplatin resistant cell lines overcomes resistance(2005)
- → 78 Pt Platinum‐Based Drugs(2005)9 cited
- Anti Cancer Activity of Platinum Complexes(2011)